Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

Rheumatology (Oxford). 2019 Sep 1;58(9):1684-1686. doi: 10.1093/rheumatology/kez114.

Authors

Isabel Mortimer^{1

2}, Lesley-Anne Bissell^{1

2}, Elizabeth M A Hensor^{1

2}, Lukasz Kozera^{1

2}, Sarah L Mackie^{1

2}, Agata N Burska^{1

2}, Jackie L Nam^{1

2}, Helen Keen^{1

2}, Edith Villeneuve^{1

2}, Helena Donica³, Maya H Buch^{1

2}, Philip G Conaghan^{1

2}, Paul Emery^{1

2}, Ann W Morgan⁴, Jacqueline Andrews^{1

2}

Affiliations

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds.
² NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
³ Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland.
⁴ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
Biomarkers / blood
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Drug Therapy, Combination
Early Diagnosis
Female
Follow-Up Studies
Humans
Infliximab / therapeutic use
Male
Methotrexate / therapeutic use
Methylprednisolone / therapeutic use
Middle Aged

Substances

Antirheumatic Agents
Biomarkers
Infliximab
Methylprednisolone
Methotrexate

Grants and funding